Semaglutide is ideally suited for adults who are obese or overweight , either with a body mass index (BMI) over 30, or a BMI of 2530 and at least one other complication that is related to body weight, such as insulin resistance, glucose intolerance, type 2 diabetes, high blood pressure, high cholesterol, hypertension, sleep apnea, arthritis, or cardiovascular disease
As GLP-1-based therapies reshape diabetes and obesity care, ongoing post-marketing safety monitoring will be essential to ensure that benefits continue to outweigh risks across diverse patient groups. She added future research may continue evaluating long-term and rare [GI] outcomes, particularly as these agents are increasingly prescribed for weight management in individuals without diabetes. For more information: Wajd Alkabbani, PhD, can be reached at [email protected].
Transient mood shifts or increased emotional sensitivity, particularly in patients with underlying stress-related conditions
What is the difference between GRAS approval and drug approval
